You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
|
|---|---|
| Published in |
Journal of Negative Results in BioMedicine, October 2004
|
| DOI | 10.1186/1477-5751-3-4 |
| Pubmed ID | |
| Authors |
Ee Tuan Lim, Axel Petzold, Siobhan M Leary, Daniel R Altmann, Geoff Keir, Ed J Thompson, David H Miller, Alan J Thompson, Gavin Giovannoni |
| Abstract |
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon beta-1a in subjects with PPMS. The key questions were whether S100B levels were associated with either disability or MRI findings in primary progressive MS and whether Interferon beta-1a has an effect on their S100B levels. Serial serum S100B levels were measured using an ELISA method. The results demonstrated that serum S100B is not related to either disease progression or MRI findings in subjects with primary progressive MS given Interferon beta-1a. Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures. |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 4% |
| Unknown | 24 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 20% |
| Student > Bachelor | 3 | 12% |
| Student > Master | 3 | 12% |
| Other | 2 | 8% |
| Professor | 2 | 8% |
| Other | 5 | 20% |
| Unknown | 5 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 36% |
| Nursing and Health Professions | 3 | 12% |
| Neuroscience | 3 | 12% |
| Agricultural and Biological Sciences | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 6 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2012.
All research outputs
#5,328,170
of 25,374,647 outputs
Outputs from Journal of Negative Results in BioMedicine
#28
of 113 outputs
Outputs of similar age
#12,169
of 75,851 outputs
Outputs of similar age from Journal of Negative Results in BioMedicine
#1
of 3 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 113 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 75,851 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them